Price$4.29-0.05 (-1.27%)
01:30 PM07:45 PM
News · 26 weeks61+800%
2026-01-182026-07-12
Mix3390d
- Insider20(61%)
- Other6(18%)
- SEC Filings4(12%)
- Earnings2(6%)
- Offering1(3%)
Latest news
25 items- PRTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference CallTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the call, dial-in details will be provided in an auto-generated email containing a link
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERChief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERCEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSzela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)5 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERMarshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)5 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERNew insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- PRTriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver CancerNewly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERChief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERCEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECSEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.SCHEDULE 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERDirector Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Hicks Kerry R was granted 28,201 shares, increasing direct ownership by 5% to 542,790 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Wahlstrom Mats was granted 71,828 shares, increasing direct ownership by 457% to 87,555 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Stansky Michael P was granted 43,590 shares, increasing direct ownership by 6% to 830,722 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Valle William was granted 52,754 shares, increasing direct ownership by 173% to 83,241 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Matlin David J was granted 51,266 shares, increasing direct ownership by 4% to 1,323,210 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
TLSI FAQ
6 questionsWhere does TLSI stock trade?
TriSalus Life Sciences Inc. (TLSI) is listed on NASDAQ.What sector and industry is TLSI in?
TriSalus Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did TriSalus Life Sciences Inc. go public?
TriSalus Life Sciences Inc. (TLSI) completed its IPO in 2021.What are analysts saying about TLSI?
TriSalus Life Sciences Inc. has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy on 2025-02-13. Recent price targets range from $1000.00 to $1250.00.What companies are similar to TLSI?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare TLSI side-by-side with any of them on Quantisnow.How can I track TLSI on Quantisnow?
Quantisnow aggregates TriSalus Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLSI to receive live email and push alerts on every new disclosure.